Related Experiment Video
Updated: Jun 22, 2026
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Clinical Trial of Autologous Dendritic Cell Administration Effect on Water Molecule Diffusion and Anti-Inflammatory
Paulus Stefanus Dimu1,2, Aziza Ghanie Icksan1, Farhat1
1Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia.
Abstract:
Diabetic kidney disease (DKD) significantly increases mortality, with patients facing a fourfold risk of death within ten years. Chronic inflammation, marked by transforming growth factor-β (TGF-β) and intracellular adhesion molecule-1 (ICAM-1) activity, contributes to kidney damage and fibrosis. This study investigates the effect of autologous dendritic cells on inflammation and kidney function, focusing on apparent diffusion coefficient (ADC), TGF-β, and ICAM-1 levels. This quasi-experimental clinical trial involved 22 DKD patients at Gatot Soebroto Army Hospital. Patients received autologous dendritic cell injections. Baseline and post-intervention magnetic resonance imaging (MRI) scans measured ADC values, and ICAM-1 and TGF-β levels were analyzed. Post intervention, the median ADC decreased from 1.75 mm2/s to 1.64 mm2/s (p = 0.223). ICAM-1 levels increased significantly in females (p = 0.04) but not in males (p = 0.35). No significant changes were found in TGF-β levels (p = 0.506). ADC changes were statistically insignificant and did not correlate with CKD severity. ICAM-1 increases in females correlated with improved creatinine levels, suggesting kidney function improvement. Autologous dendritic cell therapy revealed potential gender-specific immune responses but showed limited overall biomarker improvements. Further studies are required to validate its therapeutic value.
Insights
Autologous dendritic cell therapy for diabetic kidney disease showed potential gender-specific immune responses but limited overall biomarker improvements. Further research is needed to confirm its therapeutic value in managing kidney inflammation and function.
Area of Science:
- Nephrology
- Immunology
- Biomedical Engineering
Background:
- Diabetic kidney disease (DKD) is a major cause of mortality, linked to chronic inflammation.
- Transforming growth factor-β (TGF-β) and intracellular adhesion molecule-1 (ICAM-1) are key inflammatory markers in kidney damage.
- Understanding inflammation's role is crucial for developing effective DKD treatments.
Purpose of the Study:
- To investigate the impact of autologous dendritic cell therapy on inflammation and kidney function in DKD patients.
- To assess changes in apparent diffusion coefficient (ADC), TGF-β, and ICAM-1 levels post-intervention.
- To explore potential gender-specific responses to the therapy.
Main Methods:
- A quasi-experimental clinical trial involving 22 DKD patients.
- Administration of autologous dendritic cell injections.
- Assessment of ADC via MRI, and analysis of TGF-β and ICAM-1 serum levels before and after treatment.
Main Results:
- Median ADC showed an insignificant decrease (1.75 to 1.64 mm²/s, p=0.223).
- ICAM-1 levels significantly increased in females (p=0.04) but not males (p=0.35).
- No significant changes in TGF-β levels (p=0.506); ADC changes did not correlate with CKD severity.
Conclusions:
- Autologous dendritic cell therapy may elicit gender-specific immune responses in DKD patients.
- The therapy demonstrated limited overall improvement in key biomarkers.
- Further research is warranted to validate the therapeutic potential and understand gender-specific effects.
More Related Videos
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
